Aranoza in the Treatment of Metastatic Neuroendocrine Tumors (NETs): Single Institution Experience
#1275
Introduction: Aranoza (3-α-L-arabinopyranosyl-1-methyl-nitrosourea) – nitrosourea derivative, as STZ.
Aim(s): To evaluate the efficacy and safety of Aranoza in metastatic WD NETs
Materials and methods: We performed a prospective analysis of all pts treated with Aranoza (500 mg/m2 for 3 days every 3 weeks) at our center between July 2007 and July 2014. The median progression-free survival was calculated using Kaplan-Meier method. Treatment efficacy was evaluated according to RECIST
Conference: 13th Annual ENETSConcerence (2016)
Presenting Author:
Authors: Gorbunova V, Orel N, Kuzminov A, Emelianova G, Odintsova A,
Keywords: aranoza, Neuroendocrine tumors, chemotherapy,
To read the full abstract, please log into your ENETS Member account.